Sipuleucel-T API Manufacturers
compare suppliers & get competitive offers
Filters
Reset
Selected filters:
Type
Production region
Qualifications
To view suppliers for this material, you need to be logged in first.
This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.
Looking for Sipuleucel-T API 917381-47-6?
- Description:
- Here you will find a list of producers, manufacturers and traders of Sipuleucel-T. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Sipuleucel-T
- Synonyms:
- Sipuleucel-T , Sipuleucel-T , Sipuleucel-T
- Cas Number:
- 917381-47-6
- DrugBank number:
- DB06688
- Unique Ingredient Identifier:
- 8Q622VDR18
About Sipuleucel-T
Want to know more about Sipuleucel-T? Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient.
In metastatic prostate cancer, it has extended survival by median. months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation. Sipuleucel-T was approved by the USA Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014.
You can find more info about this product by clicking on the DB ID above.
